Aging affect the anti-tumor potential of dendritic cell vaccination, but it can be overcome by co-stimulation with anti-OX40 or anti-4-1BB

Experimental Gerontology

Volumn 41, Issue 1, 2006, Pages 78-84

  Sharma, Sanjay ^a   Lucia Dominguez, Ana ^a   Lustgarten, Joseph ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Aging; Anti 4 1BB; Anti OX40; Co stimulation; Dendritic cells

Indexed keywords

DENDRITIC CELL VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 134; MONOCLONAL ANTIBODY CD 137; RECOMBINANT INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CELL AGING; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG RESPONSE; GROWTH INHIBITION; IMMUNOPHARMACOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SENESCENCE; TUMOR GROWTH;

ADENOCARCINOMA; AGING; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD137; APOPTOSIS; CANCER VACCINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; IMMUNIZATION; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 29744451992     PISSN: 05315565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exger.2005.10.002     Document Type: Article

References (39)

1. P. Bansal-Pakala, and M. Croft Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137) J. Immunol. 169 2002 5005 5009
2. E.T. Bloom, H. Umehara, R.C. Bleackley, K. Okumura, H. Mostowski, and J.T. Babbitt Age-related decrement in cytotoxic T lymphocyte (CTL) activity is associated with decreased levels of mRNA encoded by two CTL-associated serine esterase genes and the perforin gene in mice Eur. J. Immunol. 20 1990 2309 2316
3. M.P. Chang, T. Makinodan, W.J. Peterson, and B.L. Strehler Role of T cells and adherent cells in age-related decline in murine interleukin 2 production J. Immunol. 129 1982 2426 2430
4. E. Degl'Innocenti, M. Grioni, A. Boni, A. Camporeale, M.T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N.M. Greenberg, and M. Bellone Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization Eur. J. Immunol. 35 2005 66 75
5. A. Donnini, K. Argentati, R. Mancini, A. Smorlesi, B. Bartozzi, G. Bernardini, and M. Provinciali Phenotype, antigen-presenting capacity, and migration of antigen-presenting cells in young and old age Exp. Gerontol. 37 2002 1097 1112
6. C.R. Engwerda, B.S. Fox, and B.S. Handwerger Cytokine production by T lymphocytes from young and aged mice J. Immunol. 156 1996 3621 3630
7. O.J. Finn Cancer vaccines: between the idea and the reality Nat. Rev. Immunol. 3 2003 630 641
8. N. Fleshner Defining high-risk prostate cancer: current status Can. J. Urol. 12 Suppl. 1 2005 16 94
9. P.M. Flood, X. Liu, R. Alexander, H. Schreiber, and S. Haque Loss of resistance to a highly immunogenic tumor with age corresponds to the decline of CD8 T cell activity J. Immunother. 21 1998 307 316
10. J.R. Gingrich, R.J. Barrios, R.A. Morton, B.F. Boyce, F.J. DeMayo, M.J. Finegold, R. Angelopoulou, J.M. Rosen, and N.M. Greenberg Metastatic prostate cancer in a transgenic mouse Cancer Res. 56 1996 4096 4102
11. I. Gramaglia, A.D. Weinberg, M. Lemon, and M. Croft Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses J. Immunol. 161 1998 6510 6517
12. C. Gravekamp Tailoring cancer vaccines to the elderly: the importance of suitable mouse models Mech. Ageing Dev. 122 2001 1087 1105
13. N.M. Greenberg, F. DeMayo, M.J. Finegold, D. Medina, W.D. Tilley, J.O. Aspinall, G.R. Cunha, A.A. Donjacour, R.J. Matusik, and J.M. Rosen Prostate cancer in a transgenic mouse Proc. Natl Acad. Sci. USA 92 1995 3439 3443
14. L. Haynes, P.J. Linton, S.M. Eaton, S.L. Tonkonogy, and S.L. Swain Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice J. Exp. Med. 190 1999 1013 1024
15. L. Haynes, S.M. Eaton, E.M. Burns, M. Rincon, and S.L. Swain Inflammatory cytokines overcome age-related defects in CD4 T cell responses in vivo J. Immunol. 172 2004 5194 5199
16. K. Inaba, M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor J. Exp. Med. 176 1992 1693 1702
17. J. Jiang, F. Anaraki, K.J. Blank, and D.M. Murasko T cells from aged mice are resistant to depletion early during virus infection J. Immunol. 171 2003 3353 3357
18. J. LeMaoult, P. Szabo, and M.E. Weksler Effect of age on humoral immunity, selection of the B-cell repertoire and B-cell development Immunol. Rev. 160 1997 115 126
19. T.L. Lung, M. Saurwein-Teissl, W. Parson, D. Schonitzer, and B. Grubeck-Loebenstein Unimpaired dendritic cells can be derived from monocytes in old age and can mobilize residual function in senescent T cells Vaccine 18 2000 1606 1612
20. J. Lustgarten, J. Marks, and L.A. Sherman Redirecting effector T cells through their IL-2 receptors J. Immunol. 162 1999 359 365
21. J. Lustgarten, A.L. Dominguez, and M. Thoman Aged mice develop protective antitumor immune responses with appropriate costimulation J. Immunol. 173 2004 4510 4515
22. J. Lustgarten, A.L. Dominguez, and C. Cuadros The CD8+ T cell repertoire against Her-2/neu antigens in neu transgenic mice is of low avidity with antitumor activity Eur. J. Immunol. 34 2004 752 761
23. L. Malaguarnera, L. Ferlito, S. Di Mauro, R.M. Imbesi, G. Scalia, and M. Malaguarnera Immunosenescence and cancer: a review Arch. Gerontol. Geriatr. 32 2001 77 93
24. J.N. Mittler, and W.T. Lee Antigen-specific CD4 T cell clonal expansion and differentiation in the aged lymphoid microenvironment. II. The memory T cell response is diminished Mech. Ageing Dev. 125 2004 59 68
25. L.A. Norian, and P.M. Allen No intrinsic deficiencies in CD8+ T cell-mediated antitumor immunity with aging J. Immunol. 173 2004 835 844
26. M.A. Pahlavani, and A. Richardson The effect of age on the expression of interleukin-2 Mech. Ageing Dev. 89 1996 125 154
27. J. Plowden, M. Renshaw-Hoelscher, S. Gangappa, C. Engleman, J.M. Katz, and S. Sambhara Impaired antigen-induced CD8+ T cell clonal expansion in aging is due to defects in antigen presenting cell function Cell. Immunol. 229 2004 86 92
28. M. Provinciali, K. Argentati, and A. Tibaldi Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice Gene Ther. 7 2000 624 632
29. M. Provinciali, A. Smorlesi, A. Donnini, B. Bartozzi, and A. Amici Low effectiveness of DNA vaccination against HER-2/neu in ageing Vaccine 21 2003 843 848
30. B. Rini Recent development of dendritic cell-based immunotherapy for prostate cancer Expert Opin. Biol. Ther. 4 2004 1729 1734
31. M. Schnurr, P. Galambos, C. Scholz, F. Then, M. Dauer, S. Endres, and A. Eigler Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines Cancer Res. 61 2001 6445 6450
32. W.W. Shuford, K. Klussman, D.D. Tritchler, D.T. Loo, J. Chalupny, A.W. Siadak, T.J. Brown, J. Emswiler, H. Raecho, C.P. Larsen, T.C. Pearson, J.A. Ledbetter, A. Aruffo, and R.S. Mittler 4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses J. Exp. Med. 186 1997 47 55
33. R. Solana, and G. Pawelec Molecular and cellular basis of immunosenescence Mech. Ageing Dev. 102 1998 115 129
34. L. Song, Y.H. Kim, R.K. Chopra, J.J. Proust, J.E. Nagel, A.A. Nordin, and W.H. Adler Age-related effects in T cell activation and proliferation Exp. Gerontol. 28 1993 313 321
35. M. Sznol, and D.R. Parkinson Clinical applications of IL-2 Oncology (Huntingt) 8 1994 61 67 (74-65)
36. C. Takahashi, R.S. Mittler, and A.T. Vella Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal J. Immunol. 162 1999 5037 5040
37. V.Y. Taraban, T.F. Rowley, L. O'Brien, H.T. Chan, L.E. Haswell, M.H. Green, A.L. Tutt, M.J. Glennie, and A. Al-Shamkhani Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses Eur. J. Immunol. 32 2002 3617 3627
38. A.D. Weinberg, M.M. Rivera, R. Prell, A. Morris, T. Ramstad, J.T. Vetto, W.J. Urba, G. Alvord, C. Bunce, and J. Shields Engagement of the OX-40 receptor in vivo enhances antitumor immunity J. Immunol. 164 2000 2160 2169
39. X. Zhang, H. Fujii, H. Kishimoto, E. LeRoy, C.D. Surh, and J. Sprent Aging leads to disturbed homeostasis of memory phenotype CD8(+) cells J. Exp. Med. 195 2002 283 293